Lord, Abbett & Co. LLC Macrogenics Inc Transaction History

Lord, Abbett & Co. LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$15.91 - $21.88 $4.48 Million - $6.15 Million	-281,307 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$19.74 - $28.7 $72,524 - $105,443	-3,674 Reduced 1.29%	281,307 $5.89 Million
Q2 2021 Aug 11, 2021	BUY	$20.49 - $35.63 $5.84 Million - $10.2 Million	284,981 New	284,981 $7.66 Million
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $9.22 Million - $13 Million	-741,191 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $1.41 Million - $1.92 Million	97,321 Added 15.12%	741,191 $12.6 Million
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $7.15 Million - $16.5 Million	643,870 New	643,870 $11.6 Million

130

55.7M

28.3K

197K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $77.4M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.